AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03902756 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Endotracheal cuff inflation
Description: Endotracheal cuff inflation is putting the air in to the endotracheal tube cuff to make the proper sealing.
Study NCT03902756 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Endotracheal cuff inflation
Description: Endotracheal cuff inflation is putting the air in to the endotracheal tube cuff to make the proper sealing.
Study NCT01072032 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Anklebot (Ankle Robot)
Description: Impedance controlled ankle robot provides assistance as needed for participants to perform ankle movements while playing a video game, is used to assist stroke patients to enhance motor recovery
Study NCT01072032 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anklebot (Ankle Robot)
Description: Impedance controlled ankle robot provides assistance as needed for participants to perform ankle movements while playing a video game, is used to assist stroke patients to enhance motor recovery
Study NCT00638157 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: daptomycin
Description: Intravenous (i.v.) 6 mg/kg q24h
Study NCT00638157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daptomycin and gentamicin
Description: i.v. daptomycin 6 mg/kg q24h plus initial i.v. gentamicin
Study NCT00564369 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CDC HIV testing recommendations
Description: Current vs. prior CDC recommendations
Study NCT00564369 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CDC HIV testing recommendations
Description: Current vs. prior CDC recommendations
Study NCT04101136 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin - placebo controlled clinical trial
Description: The participants will get the medication supply every month along with the refill of antiretroviral drugs. The drug and placebo tablets will be administered to patients by a staff member who are privy to the treatment. In the end of every month, each participant should return the unused pills every month
Study NCT04101136 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atorvastatin - placebo controlled clinical trial
Description: The participants will get the medication supply every month along with the refill of antiretroviral drugs. The drug and placebo tablets will be administered to patients by a staff member who are privy to the treatment. In the end of every month, each participant should return the unused pills every month
Study NCT04225273 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sculptra Aesthetic 8 ml and Lidocaine
Description: Treatment of nasolabial folds
Study NCT00411697 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Engerix™-B Kinder
Description: Intramuscular injection, 1 dose
Study NCT01344408 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computer-training
Description: The computer-training program Move IT To Improve IT is a exercise program which is installed and used on a Apple Imac in the patients home to support vestibular rehabilitation
Study NCT01741480 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early warning system monitoring.
Description: General hospital ward patients will be monitored 24/7 for clinical deterioration using the early warning system monitoring developed at Washington University.
Study NCT01741480 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: routine care
Study NCT00218686 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: psychoeducational
Description: psychoeducational
Study NCT00218686 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: control
Description: VTC
Study NCT00927888 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Block
Description: Bupivacaine local anesthesia block prior to start of FESS procedure.
Study NCT00927888 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo is identical in appearance in comparison to active drug.
Study NCT01182714 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: immediate removal of in-dwelling catheter
Study NCT01182714 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: 24 hours delayed removal of catheter
Study NCT03094208 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dual task balance training
Description: balance exercises with cognitive and motor dual tasks
Study NCT03094208 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traditional balance training
Description: balance exercises
Study NCT00693784 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biostat® Disc Augmentation System
Description: Delivery of Biostat BIOLOGX® Fibrin Sealant with the Biostat Delivery Device
Study NCT01026610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LB80380 90 mg
Description: LB80380 90 mg + placebo tablets, once daily, for 48 weeks
Study NCT01026610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LB80380 150 mg
Description: LB80380 60 mg + 90 mg tablets, once daily, for 48 weeks
Study NCT01026610 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: entecavir 0.5 mg
Description: entecavir 0.5 mg tablet, once daily, for 48 weeks
Study NCT03857685 — intervention group
Intervention type: PROCEDURE
Intervention: In-vitro model
Description: In-vitro model of posterior capsule opacification by culturing the lens capsule
Study NCT02641093 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: 60-66 Gy over 6 weeks
Study NCT02641093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Weekly during radiation therapy for 6 doses only for patients with high risk pathological features
Study NCT02370784 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atorvastatin
Description: Atorvastatin is an oral cholesterol-lowering medication commonly referred to as statin therapy.
Study NCT02370784 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral drug of similar appearance to atorvastatin
Study NCT03639597 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VytronUS Ablation System
Study NCT01657487 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone/Salmeterol high dose
Study NCT01657487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone/Salmeterol high dose
Study NCT03165890 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACETAZOLAMIDE oral capsule
Description: Administration of 125mg acetazolamide in the morning, 250mg in the evening, starting 24 hours before departure to 3200m
Study NCT03165890 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3200m
Study NCT03780933 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin c
Description: vitamin c IV 10 G
Study NCT02685761 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Midline Vertical
Description: Cesarean section performed using a midline vertical skin incision, located between the umbilicus and pubis
Study NCT02685761 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High Transverse
Description: Cesarean section performed using a transverse skin incision located above the pannus
Study NCT03504332 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intracanal disinfection in revascularization
Description: a procedure to create vital cells in the pulp space of immature teeth which enables thickening of the dentinal walls of the root.
Study NCT03504332 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intracanal disinfection in revascularization
Description: a procedure to create vital cells in the pulp space of immature teeth which enables thickening of the dentinal walls of the root.
Study NCT02514187 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cyclotron-produced 99mTc
Description: Each research subject will serve as his/her own control, and will undergo imaging using both generator- and cyclotron-produced 99mTc. The study will follow the usual clinical procedure for routine imaging in the nuclear medicine department.~All subjects will be contacted by phone or in person the day following the injection of both generator and cyclotron-produced 99mTc to monitor for potential adverse events.
Study NCT02514187 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Generator-produced 99mTc
Description: Each research subject will serve as his/her own control, and will undergo imaging using both generator- and cyclotron-produced 99mTc. The study will follow the usual clinical procedure for routine imaging in the nuclear medicine department.~All subjects will be contacted by phone or in person the day following the injection of both generator and cyclotron-produced 99mTc to monitor for potential adverse events.
Study NCT03808220 — intervention group
Intervention type: BEHAVIORAL
Intervention: postoperative pain intensity
Description: estimate the postoperative pain intensity by using a scaling system via questionnaire
Study NCT03808220 — intervention group
Intervention type: BEHAVIORAL
Intervention: preoperative pain frequency
Description: estimate the preoperative pain intensity by using a scaling system via questionnaire
Study NCT03808220 — intervention group
Intervention type: BEHAVIORAL
Intervention: Side effect
Description: investigate the presence of any side effect
Study NCT02921997 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent influenza A/H7N9 virus vaccine
Description: Monovalent influenza A/H7N9 virus vaccine.
Study NCT04266093 — intervention group
Intervention type: DRUG
Intervention: GeneTherapy
Description: Observation/ Gene Therapy Long-term Follow-up. Subjects who have received treatment on an applicable NCI CIO gene therapy protocol.
Study NCT01608802 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Palliative care
Description: Regular appointments with an existing clinic nurse who has been trained in palliative care, the patient is asked about their physical, psychological, social and spiritual problems, and a care management plan devised with referral as necessary.
Study NCT01608802 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Patients attend monthly for their ART monitoring and prescription filling, and a multiprofessional team is available as necessary.
Study NCT02869347 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conestat alfa
Description: Two intravenous injections (over 5 minutes) of Conestat alfa immediately pre-procedure (elective coronary angiography) and 4 hours later; for patients less than 84kg at a dose of 50 U/kg, and for patients of 84kg body weight or greater at a dose of 4200 U.
Study NCT02869347 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium chloride 0.9%
Description: Two intravenous injections of sodium chloride 0.9% (maximum 28 ml, matching the respective amount of the Conestat alfa arm) immediately pre-procedure (elective coronary angiography) and 4 hours later.
Study NCT00593723 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT
Study NCT02825017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coppertone (BAY 987517)
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2mg/cm\*2 test application.(Formulation-SR15-79_Y73-161)
Study NCT03074825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chiauranib
Description: Take 50mg orally once daily
Study NCT03925948 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PLAN 4 Success-Diabetes
Description: The study intervention-PLAN 4 Success-Diabetes-consisted of four 1 to 1 ½-hour weekly health literacy training and disease knowledge education sessions for four weeks (4 in-person sessions), followed by two home visits and monthly phone counseling for over 6 months (5 phone sessions). The intervention is theory-driven and builds on von Wagner's model to incorporate key elements such as health literacy, disease knowledge, and self-efficacy for better glucose outcomes.
Study NCT03547375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib 500mg/d po,28 days as one cycle
Study NCT04327414 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: Standing desks
Study NCT04111874 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Teletherapy LTA
Description: Participating families will receive a copy of the book 'Helping Your Anxious Child, 2nd Edition', as well as the companion parent and child workbooks, to use at home and in session with the therapist. During each of the four videoconferencing sessions, therapists will serve to provide encouragement and support as the parent works through the program independently.
Study NCT04111874 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Teletherapy STA
Description: Participating families will also receive a copy of the book 'Helping Your Anxious Child, 2nd Edition', as well as the companion parent and child workbooks, to use at home and in session with the therapist. During each of the ten videoconferencing sessions, therapists will guide the parent through the implementation of the program, including explaining materials, assisting to develop planned therapy activities with the child, and problem-solving as needed.
Study NCT04116398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone with 2 loading doses followed by PRN regimen.
Description: * Loading dose with 2 systematic intravitreal injections (IVI) of ozurdex at the baseline and 12 weeks.Followed by a PRN regimen with strict retreatment criteria (already used and published in the Prediamex study, Bellocq,Kodjikian et al Ophthalmology Retina 2017)~* Retreatment criteria: Reduction in VA ≥ 5 ETDRS Letters; and/or CSMT ≥ 275 microns by OCT-Cirrus® or ≥ 285 microns by OCT Spectralis®/Topcon; and/or increase of CSMT > 50 microns; and/or onset of recurrent retinal cysts; and/or residual edema considered by the practitioner to be clinically significant.~* Minimal time limit between two IVI : 12 weeks~* Visits: monthly during 1 year (to check efficacy and safety) and then for the 2nd-year only at Month18 (M18) and Month 24 (M24)
Study NCT02107521 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intracytoplasmic morphologically selected sperm injection
Description: Sperm selection for injection will be performed at 6600x magnification
Study NCT03526861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tralokinumab
Description: Tralokinumab is a human recombinant monoclonal antibody of the immunoglobulin G4 (IgG4) subclass that specifically binds to human interleukin (IL) 13 and blocks interaction with the IL-13 receptors.
Study NCT02107521 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intracytoplasmic sperm injection
Description: sperm selection for injection will be performed under 400x magnification
Study NCT01634698 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: retinyl palmitate (UNICEF, Melbourne, Australia)
Description: the patients received an oral dose of 1500 IU or 2500 IU, once.
Study NCT04241250 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EAW+SCES (exoskelton and spinal cord epidural stimulation)
Description: Three months of exoskeleton training followed by 6 months of epidural stimulation.
Study NCT03526861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Description: Placebo contains the same excipients in the same concentration only lacking tralokinumab.
Study NCT04146792 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: body acceptance program
Description: Complete 3 writing exercises over the course of week. Each writing exercise will take approximately 15 minutes to complete
Study NCT04146792 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: writing creatively program
Description: Complete 3 writing exercises over the course of week. Each writing exercise will take approximately 15 minutes to complete
Study NCT00901550 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: All participants received oral Methotrexate(MTX), starting at 7.5 mg/week. In patients with persistent tender or swollen joints, the dose was escalated in a graduated manner (2.5 mg/week every 1-2 weeks) to 15 mg/week by week 4 or 20 mg/week by week 8
Study NCT00901550 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infliximab
Description: Patients in combination group receive infliximab 3mg/kg at weeks 0, 2, and 6 and every 8 week thereafter.
Study NCT01169064 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Silver-containing surgical dressing
Description: Dressing placed over surgical incision and remain for 3-5 days
Study NCT01169064 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cloth adhesive dressing
Description: Cloth adhesive dressing placed over surgical incision and remains for 3-5 days
Study NCT03638804 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 89Zr-KN035
Description: Single injection of 89Zr labeled KN035 in subjects to observe KN035 affinity in PD-L1 expressed Solid tumors by using PET imaging.
Study NCT03856125 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PENS plus exercise
Description: The technique will be performed ultrasound-guided on the radial nerve, the places of the needle's insertions will be the following:~* Needle will be placed at under the lateral intermuscular septum between the triceps brachii and brachialis, approximately 10cm superior to the lateral epicondyle~* Needle will be placed at the upper third of the forearm on the posterior interosseous nerve after passing the arcade of Froshe's~The percutaneous electrical stimulation will be realized with a transcutaneous electric nerve stimulation (TENS) current:~* TENS Frequency - 2 Hz~* TENS Pulse width - 250 microseconds~* Duration - 30 minutes.~* TENS Intensity - Increased at an intensity of visible motor response of the innervated musculature and maximal tolerable intensity.~* Administration - One per week
Study NCT03856125 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham PENS plus exercise
Description: The technique will be performed on the radial nerve, the places of the needle's. The technique will be performed ultrasound-guided on the radial nerve, the places of the needle's insertions will be the following:~* Needle will be placed at under the lateral intermuscular septum between the triceps brachii and brachialis, approximately 10cm superior to the lateral epicondyle.~* Needle wil be placed at the at the upper third of the forearm on the posterior interosseous nerve after passing the arcade of Froshe's.~The current will not be working, and the needles will be placed during 30 minutes.~- Administration - One per week
Study NCT04646265 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: periodontal treatment
Description: non-surgical root debridement
Study NCT04663529 — intervention group
Intervention type: OTHER
Intervention: contact lens
Description: daily disposable soft contact lens
Study NCT03550677 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: general anesthesia
Description: The patient will be monitored with ECG, pulse oximetry and noninvasive blood pressure. Anesthesia will be induced using 2-2.5 mg/kg propofol, 1-2 mcg/kg fentanyl, 10-20 mg rocuronium and proper size Laryngeal mask airway will be placed securely the airway.
Study NCT03550677 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ankle block
Description: ankle nerve block will be performed in group ankle block patients using a mixture of 5 ml of 2% lidocaine and 10 ml of 0.5% bupivacaine and same amount placebo (saline) in groups placebo under the guidance of peripheral nerve stimulator the anesthesia will be discontinued and LMA will be removed. The patients will be transferred from postoperative care unit to the ward after they are eligible for discharge according to modified Aldrete scoring system.
Study NCT04643977 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mARG-01-17 (mesohyal AGRIBENONE)
Description: Dermal Filler
Study NCT04931030 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary advice
Description: Subjects are provided dietary advice by the dietitians as part of the research team/ investigators
Study NCT04276246 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: dental implants and retentive implant components
Description: retentive components (Group A Test), which are connected to the implants to retain the RPD
Study NCT04276246 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: dental implants and supportive implant components
Description: supportive components (Group B Control), which are connected to the implants to support the RPD